Drug Profile
Anti-CD48 monoclonal antibody WM-63
Latest Information Update: 22 Aug 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 19 Nov 1998 New profile
- 19 Nov 1998 Phase-I clinical trials for Chronic lymphocytic leukaemia in Australia (IV)